zilucoplan

FDA Drug Profile — ZILBRYSQ

Drug Details

Generic Name
zilucoplan
Brand Names
ZILBRYSQ
Application Number
NDA216834
Sponsor
UCB, Inc.
NDC Codes
3
Dosage Forms
INJECTION, SOLUTION
Routes
SUBCUTANEOUS
Active Ingredients
ZILUCOPLAN

Indications and Usage

1 INDICATIONS AND USAGE ZILBRYSQ is indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive. ZILBRYSQ is a complement inhibitor indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive. ( 1 )